Protagonist Therapeutics, Inc. $PTGX Stock Holdings Lifted by Boxer Capital Management LLC

Boxer Capital Management LLC grew its position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) by 83.3% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 110,000 shares of the company’s stock after purchasing an additional 50,000 shares during the period. Protagonist Therapeutics comprises about 2.3% of Boxer Capital Management LLC’s holdings, making the stock its 12th largest position. Boxer Capital Management LLC owned approximately 0.18% of Protagonist Therapeutics worth $7,307,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in PTGX. Royal Bank of Canada grew its stake in shares of Protagonist Therapeutics by 30.6% in the 1st quarter. Royal Bank of Canada now owns 9,964 shares of the company’s stock valued at $482,000 after buying an additional 2,334 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Protagonist Therapeutics by 0.9% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 37,403 shares of the company’s stock valued at $1,810,000 after acquiring an additional 348 shares in the last quarter. Millennium Management LLC lifted its stake in Protagonist Therapeutics by 283.6% in the first quarter. Millennium Management LLC now owns 134,269 shares of the company’s stock valued at $6,493,000 after acquiring an additional 99,269 shares during the last quarter. Envestnet Asset Management Inc. lifted its stake in Protagonist Therapeutics by 43.2% in the second quarter. Envestnet Asset Management Inc. now owns 23,878 shares of the company’s stock valued at $1,320,000 after acquiring an additional 7,199 shares during the last quarter. Finally, Bank of Montreal Can grew its position in Protagonist Therapeutics by 7.2% in the second quarter. Bank of Montreal Can now owns 9,578 shares of the company’s stock worth $533,000 after acquiring an additional 642 shares in the last quarter. 98.63% of the stock is owned by hedge funds and other institutional investors.

Protagonist Therapeutics Stock Performance

Shares of NASDAQ:PTGX opened at $92.36 on Friday. The company has a market cap of $5.89 billion, a P/E ratio of -45.05 and a beta of 2.23. The stock’s 50-day moving average is $85.52 and its 200-day moving average is $79.66. Protagonist Therapeutics, Inc. has a 52-week low of $39.60 and a 52-week high of $98.32.

Protagonist Therapeutics (NASDAQ:PTGX) last issued its quarterly earnings results on Wednesday, February 25th. The company reported ($0.69) EPS for the quarter, missing the consensus estimate of ($0.53) by ($0.16). Protagonist Therapeutics had a negative return on equity of 19.89% and a negative net margin of 282.83%.The business had revenue of $7.44 million during the quarter, compared to the consensus estimate of $14.92 million. As a group, equities analysts predict that Protagonist Therapeutics, Inc. will post 2.43 EPS for the current year.

Insider Buying and Selling at Protagonist Therapeutics

In other Protagonist Therapeutics news, Director William D. Waddill sold 20,000 shares of the stock in a transaction on Friday, February 6th. The shares were sold at an average price of $83.68, for a total value of $1,673,600.00. Following the completion of the sale, the director directly owned 7,825 shares of the company’s stock, valued at $654,796. This represents a 71.88% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Asif Ali sold 46,203 shares of the firm’s stock in a transaction on Tuesday, January 27th. The stock was sold at an average price of $83.13, for a total transaction of $3,840,855.39. Following the completion of the sale, the chief financial officer owned 60,320 shares in the company, valued at $5,014,401.60. This represents a 43.37% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 203,167 shares of company stock valued at $16,889,199 in the last three months. 4.90% of the stock is owned by insiders.

Analyst Ratings Changes

A number of research analysts have recently weighed in on PTGX shares. Citizens Jmp raised their price target on shares of Protagonist Therapeutics from $102.00 to $112.00 and gave the company a “market outperform” rating in a report on Thursday, February 26th. Citigroup increased their target price on shares of Protagonist Therapeutics from $98.00 to $115.00 and gave the stock a “buy” rating in a research report on Monday, December 8th. Weiss Ratings lowered Protagonist Therapeutics from a “hold (c-)” rating to a “sell (d+)” rating in a report on Tuesday, February 17th. Jefferies Financial Group boosted their price target on Protagonist Therapeutics from $95.00 to $118.00 and gave the stock a “buy” rating in a research report on Monday, February 2nd. Finally, HC Wainwright upped their price target on Protagonist Therapeutics from $80.00 to $117.00 and gave the stock a “buy” rating in a research note on Friday, January 30th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Protagonist Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $101.08.

About Protagonist Therapeutics

Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.